Related Experiment Video
Updated: Jan 18, 2026
Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
Published on: May 30, 2025
Hyperprolactinemia-associated erectile dysfunction: retrospective cohort evaluating the effect of prolactin
Marek Broul1,2,3, Aneta Hujová3, Lucie Radovnická4
1Sexology Department, Krajská zdravotní a.s., Masaryk Hospital in Ústí nad Labem, o. z., Czech Republic.
Objective:
In addition to hypogonadism, other endocrine disorders-particularly hyperprolactinemia-can significantly influence erectile dysfunction (ED) in men. The aim of our study was to evaluate the effect of normalizing prolactin (PRL) levels on erectile function in men diagnosed with ED and hyperprolactinemia. The primary outcome was improvement in IIEF-5.
Methods:
We retrospectively analyzed a three group of patients (N = 20) diagnosed with hyperprolactinemia who simultaneously presented with ED, confirmed by clinical criteria and results of the International Index of Erectile Function-5 (IIEF-5) questionnaire. Group Conservative did not receive hyperprolactinemia treatment. Treatment of hyperprolactinemia consisted of pharmacotherapy with dopaminergic agonists (group Dostinex) and/or neurosurgical intervention, depending on individual findings (group Surgery). For ED therapy, each patient received one of the phosphodiesterase 5 inhibitors (PDE5I)-specifically sildenafil, tadalafil, vardenafil, or avanafil.
Results:
After successful hyperprolactinemia therapy, all treated patients achieved normalized PRL levels. At the same time, each patient showed an improvement in IIEF-5 scores, indicating a significant enhancement in erectile function. Groups Conservative showed tendency to improve. Groups Dostinex and Surgery reached significant enhancement in erectile function.
Conclusion:
Our results confirmed the positive impact of resolving the primary endocrine cause on overall sexual health. These findings underscore the importance of comprehensive hormonal assessment in the management of male sexual dysfunction, including measurement of PRL levels. While hyperprolactinemia is a relatively uncommon cause of ED, its treatment-whether pharmacological or surgical-can lead to PRL normalization and a marked improvement in erectile function. The combined use of PDE5I and hyperprolactinemia treatment represents an effective therapeutic approach that should be considered in the care of men with ED.
More Related Videos
02:21Microscopic Electric Rotary Grinding of Plaques Combined with Graft Repair in the Management of Peyronie's Disease
Published on: March 15, 2024
09:49Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
Published on: December 28, 2021
Related Concept Videos
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
01:20Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:17Male Sexual Response: Erection & Ejaculation
The blood filling the erectile tissues compresses the veins, which helps to prevent blood from leaving...